Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
Crossref DOI link: https://doi.org/10.1007/s41669-022-00366-y
Published Online: 2022-09-12
Published Print: 2023-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Felizzi, F.
Launonen, Aino http://orcid.org/0000-0003-1332-5544
Thuresson, P.-O.
Text and Data Mining valid from 2022-09-12
Version of Record valid from 2022-09-12
Article History
First Online: 12 September 2022